MedTrace Logo

Safety and Immunogenicity of Typhax, a Typhoid Vaccine

NCT03926455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-04-24

No results posted yet for this study

Summary

This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.

Conditions

  • Typhoid Fever

Interventions

BIOLOGICAL

Typhax (investigational typhoid fever candidate vaccine)

BIOLOGICAL

Placebo

Placebo is administered to the control group on Day 0 and 28

BIOLOGICAL

Active Comparator Typhim Vi

A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28

Sponsors & Collaborators

  • Matrivax Research and Development Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-28
Primary Completion
2017-02-15
Completion
2017-02-15
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03926455 on ClinicalTrials.gov